This could present a huge challenge for Moderna, which has a large portfolio of vaccines in development while also hemorrhaging cash. But with Moderna scaling back its COVID operations and demand for the shots likely being lower in the future, I would be surprised if this were still a major source of revenue for the business in five years. If it is still relying on COVID revenue, that could be a bad sign, indicating that the company hasn’t come out with more promising products forex trading fundamentals along the way.
Sales & Book Value
Top institutional shareholders of Moderna include Baillie Gifford & Co. (11.05%), FMR LLC (4.52%), State Street Corp (4.38%) and Geode Capital Management LLC (1.84%). Insiders that own company stock include Stephane Bancel, Noubar Afeyan, Stephen Hoge, Shannon Thyme Klinger, Juan Andres, James M Mock, Arpa Garay and David W Meline. Moderna Inc. is actively working to develop a range of pharmaceutical solutions and vaccines and to increase its strategic alliances. The company has seen success in its innovative mRNA technologies, and its growing partnerships have given them an edge over its competitors.
According to 17 analysts, the average rating for MRNA stock is “Hold.” The 12-month stock price forecast is $83.0, which is an increase of 101.90% from the latest price. Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about. While stock price movement reflects these multilayered dynamics, the reality of managing expectations amidst scientific innovations cannot be overstated. This blend of enthusiasm and market tethering makes the stock a curious study of growth amidst uncertainty. Earlier this month, the company swung to a surprise profit and topped revenue estimates for the third quarter following the launch earlier this year of its updated COVID-19 vaccine. Moderna head of investor relations Lavina Talukdar said at the Jefferies London Healthcare Conference on Thursday that the Cambridge, Mass.-based company sees 2028 as the year by which its revenue can sustain its business.
HSBC upgrades Moderna to Buy on pipeline potential
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free british pound sterling to hungarian forint exchange rate convert gbp guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation. As of this writing, the only commercially available product Moderna has is its COVID-19 vaccine.
The bad news is that Moderna will Backtesting take longer than originally expected to get to the break-even point. Shareholders who have already been disappointed by declining sales in recent years won’t take this lightly. And if you haven’t yet invested in Moderna, you may not see the biotech as an exciting growth player at the moment. As part of this, Moderna is cutting its R&D investment for the period of 2025 through 2028 by 20%, to $16 billion. This doesn’t mean the company will neglect its high-priority programs, though — it will actually increase its investment in oncology, for example, while slowing investment in other areas like rare-disease therapeutics.
Investment Calculator
While there’s still potential for near-term revenue tailwinds in the form of emerging infectious diseases, I’m concerned that the company may never deliver on its pipeline potential. One reason for this is the company’s extraordinary cash burn, and another is that these formative loss-making years may be negatively impacted by changing federal policy with a vaccine skeptic taking to the Department of Health and Human Services. As much as I like to take a positive opinion on Moderna, I’m bearish for now, as investing in it could be dead money.
Moderna Inc. is experiencing significant stock movement, with shares trading up by 9.62 percent on Friday, driven by developments surrounding its collaborative vaccine efforts and recent contract wins. Even at a reduced market cap of $36 billion, investors would be paying a big premium for the healthcare stock, which is why I expect Moderna’s value to decline over the next five years. The launch of the RSV vaccine is already being planned for by the company, which believes there is a $10 billion global market for this drug. In 2023, other companies sold approximately $2.3 billion in RSV vaccines, demonstrating the opportunity Moderna has in this market. What followed was a wild ride in which Moderna burst into the public consciousness as it developed and began selling one of the COVID-19 vaccines, putting the company and its mRNA technology at the forefront of investors’ minds. Nearly four years later, the company is in a curious spot as it still has only one commercially available product.
Barclays lowered their target price on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research note on Friday, November 8th. Bank of America lowered their price objective on shares of Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a research note on Friday, September 13th. UBS Group dropped their price objective on shares of Moderna from $140.00 to $108.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. Hsbc Global Res upgraded Moderna from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th.
- Several other institutional investors and hedge funds also recently added to or reduced their stakes in MRNA.
- In 2023, other companies sold approximately $2.3 billion in RSV vaccines, demonstrating the opportunity Moderna has in this market.
- You must click the activation link in order to complete your subscription.
- Moderna Inc. is experiencing significant stock movement, with shares trading up by 9.62 percent on Friday, driven by developments surrounding its collaborative vaccine efforts and recent contract wins.
Interestingly, despite the decrease, Moderna reported gross profits of around $1.35B – a testament to its strong cost management strategies, albeit shadowed by a total expense bill exceeding $1.93B. The nomination of a vaccine skeptic to the most important job in U.S. healthcare compounds my concerns about the company’s earnings trajectory. According to the current consensus forecasts — most of the forecasts were made before the MAHA nomination — Moderna won’t return to profitability until the financial year ending December 2029. In fact, the company is currently forecasted to report a loss of $9.32 in 2024 and $8.81 in 2025.